Metastatic RET-Rearranged Lung Adenocarcinomas Treated with Alectinib: Retrospective Analysis of a Single Institution

被引：0
|
作者：
Ribeiro, M. [1 ]
Gongora, A. [1 ]
Oliveira, L. [1 ]
Alessi, J. V. [1 ]
Saccardo, K. [1 ]
Zucchetti, B. [1 ]
Barbosa, F. [1 ]
Muniz, D. [1 ]
Shimada, A. [1 ]
De Souza, C. [1 ]
Feher, O. [1 ]
Katz, A. [1 ]
机构：
[1] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
alectinib; RET-rearranged;
D O I：
10.1016/j.jtho.2019.08.1852
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-67
引用
收藏
页码：S857 / S858
页数：2
相关论文
共 50 条
  • [31] The importance of RET-directed therapy in patients with RET-rearranged non-small cell lung cancer
    Yoh, Kiyotaka
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S121 - S123
  • [32] MDM2 Amplification Mediates Resistance to Cabozantinib in RET-Rearranged Lung Cancers
    Ishizawa, Kota
    Horii, Akira
    Romel, R.
    Cheng, E.
    Drilon, A.
    CANCER SCIENCE, 2018, 109 : 351 - 351
  • [33] Clinical Outcomes with Pemetrexed-Based Systemic Therapy in RET-Rearranged Lung Cancers
    Drilon, Alexander
    Bergagnini, Isabella
    Delasos, Lukas
    Sima, Camelia S.
    Smith, Roger
    Somwar, Romel
    Riely, Gregory J.
    Kris, Mark G.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S178 - S178
  • [34] Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
    Drilon, Alexander
    Lin, Jessica J.
    Filleron, Thomas
    Ni, Ai
    Milia, Julie
    Bergagnini, Isabella
    Hatzoglou, Vaios
    Velcheti, Vamsidhar
    Offin, Michael
    Li, Bob
    Carbone, David P.
    Besse, Benjamin
    Mok, Tony
    Awad, Mark M.
    Wolf, Jurgen
    Owen, Dwight
    Camidge, D. Ross
    Riely, Gregory J.
    Peled, Nir
    Kris, Mark G.
    Mazieres, Julien
    Gainor, Justin F.
    Gautschi, Oliver
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1595 - 1601
  • [35] Targeting RET-rearranged non-small-cell lung cancer: future prospects
    Bronte, Giuseppe
    Ulivi, Paola
    Verlicchi, Alberto
    Cravero, Paola
    Delmonte, Angelo
    Crino, Lucio
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 27 - 36
  • [36] Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series
    Fricke, Jeremy
    Wang, Joshua
    Gallego, Natalie
    Mambetsariev, Isa
    Kim, Pauline
    Babikian, Razmig
    Chen, Bihong T.
    Afkhami, Michelle
    Subbiah, Vivek
    Salgia, Ravi
    CLINICAL LUNG CANCER, 2023, 24 (07) : 666 - 671
  • [37] Anti-tumor activity and acquired resistance mechanism of dovitinib in RET-rearranged lung adenocarcinoma
    Kang, Chan Woo
    Jang, Kang Won
    Cho, Byoung Chul
    CANCER RESEARCH, 2015, 75
  • [38] Role of ERBB signaling in RET-rearranged lung cancer and contribution of EGFR amplification to cabozantinib resistance.
    Smith, Roger
    Drilon, Alexander E.
    Kunte, Siddharth
    Suzawa, Ken
    Hayashi, Takuo
    Delasos, Lukas
    Tai, Huichun
    Hitchman, Tyler
    Khodos, Inna
    Mattar, Marissa
    Kohsaka, Shinji
    de Stanchina, Elisa
    Lockwood, William
    Ladanyi, Marc
    Somwar, Romel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review
    Lei, Siyu
    Tian, Linyan
    Yang, Lu
    Yang, Yaning
    Li, Junling
    Hu, Xingsheng
    Hao, Xuezhi
    Xu, Haiyan
    Wang, Yan
    BMC CANCER, 2024, 24 (01)
  • [40] RET-Rearranged Squamous Cell Carcinoma of the Lung Responding to First-Line Immunotherapy plus Chemotherapy
    Gao, Q.
    Wang, Q.
    Peng, K.
    Zhang, S.
    Zhang, X.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S686 - S686
12345